BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

Fabian Gerlinghaus, Alexander Seyf, and Knut Steffensen go behind the headlines and dive into the advanced therapy ecosystem.

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies ...

COVID success story BioNTech (Nasdaq: BNTX) is to buy fellow German mRNA company CureVac (Nasdaq: CVAC). Shares in the latter ...

The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion. Under the terms of the ...